Clinical data analysis based on trimetazidine in the treatment of coronary heart disease with heart failure
YANG Bin,JIN Gui-qin,MEI Qi-bing
2012-01-01
Abstract:Objective Through literature data to evaluate the efficacy and safety of trimetazidine in the treatment of coronary heart disease with heart failure.Methods Literatures were retrieved from Medline,EMBASE,Cochrane Library,CBM,VIP,CNKI databases by computer and from relevant Chinese medical journals by hand.Trial selection, quality evaluation and information extraction were performed according to inclusion and exclusion criteria.Metaanalysis was conducted by using RevMan 5.0 software.Results Twenty five reports were identified,including 2 318 patients,in which 1 178 cases were treatment group and 1 140 cases were control group.The analysis results showed that trimetazidine improved the total clinical efficacy[94.2%vs 72.2%,OR=6.42,95%CI(4.28,9.64),Z=8.96,P<0.01]and 6 min walking distance[SMD=4.56,95%CI(33.51,84.13),Z=4.56,P<0.01];cardiac index were also improved,such as LVEF[SMD=7.14,95%CI(6.28,8.00),Z=16.25,P<0.01],LVEDD[SMD=-3.83,95%C/(-5.09,-2.57),Z=5.95, P<0.01],LVESD[SMD=-4.51,95%CI(-6.24,-2.78),Z=5.10,P<0.01]and LVEDV[SMD=-23.56,95%C/(-34.98, -12.14),Z=4.04,P<0.01];trimetazidine reduced type B brain natriuretic peptide(BNP)[SMD=-161.86,95%CI(-268.0, 55.72),Z=2.99,P=0.003].The main adverse reaction(0.85%) of trimetazidine is nausea,vomiting.Conclusion Trimetazidine can improve the total clinical efficacy and cardiac function.The long-term treatment is safe.